Obstructive Airway Diseases (Asthma, COPD)

Obstructive Airway Diseases (Asthma, COPD)

Obstructive Airway Diseases (Asthma, COPD)

On this page

OAD Overview - The Wheezy Foes

  • Obstructive Airway Diseases (OADs): Characterized by chronic inflammation and airflow limitation, primarily expiratory. Wheezing is a hallmark symptom.
  • Key Types:
    • Asthma: Reversible bronchoconstriction, bronchial hyperresponsiveness, airway inflammation. Often allergic triggers.
    • COPD (Chronic Obstructive Pulmonary Disease): Progressive, largely irreversible airflow limitation. Primarily due to smoking.
      • Chronic Bronchitis: Clinical (cough & sputum).
      • Emphysema: Pathological (alveolar destruction).
  • Spirometry: Key diagnostic tool. Shows ↓$FEV_1$, ↓$FEV_1/FVC$ ratio < 0.7. Healthy vs COPD airway cross-section

⭐ Significant reversibility in asthma is defined as an increase in $FEV_1$ by > 12% and > 200ml from baseline after bronchodilator administration.

Pathophysiology - Suffocation Science

Core: Chronic inflammation → Airflow limitation.

Asthma:

  • Triggers (allergens/irritants) → Th2-driven eosinophilic inflammation, IgE, mast cells.
  • Reversible bronchoconstriction, Airway Hyperresponsiveness (AHR), remodeling (smooth muscle hypertrophy). Normal vs Asthmatic Airway: Inflammation & Constriction

COPD:

  • Noxious stimuli (smoking) → Neutrophilic inflammation, macrophages, CD8+ T-cells.
  • Protease-antiprotease imbalance (↑elastase) → Emphysema.
  • Mucus hypersecretion → Chronic bronchitis.
  • Largely irreversible airflow limitation.

⭐ In COPD, FEV1/FVC ratio <0.7 post-bronchodilator confirms persistent airflow limitation.

Clinical & Diagnosis - Breathless Clues

  • Key Symptoms:
    • Asthma: Episodic wheeze, nocturnal cough, dyspnea. Reversible.
    • COPD: Persistent progressive dyspnea, chronic cough (sputum), exacerbations.
  • History Clues:
    • Asthma: Atopy, family Hx, triggers (allergens, exercise).
    • COPD: Smoking (> 10 pack-yrs), age > 40. AATD if young/non-smoker.
  • Examination:
    • Both: Wheeze, prolonged expiration, accessory muscles.
    • Asthma: Normal between attacks.
    • COPD: Barrel chest, pursed lips, late cyanosis.
  • Diagnostics:
    • Spirometry:
      • Asthma: ↓FEV1/FVC, reversibility (> 12% & 200ml FEV1 ↑ post-BD).
      • COPD: Post-BD FEV1/FVC < 0.7 (persistent).
    • PEFR (Asthma): Diurnal variation > 20%.
    • CXR:
      • Asthma: Often normal; attack hyperinflation.
      • COPD: Hyperinflation, bullae, flat diaphragm.

Exam Favourite: In asthma, a >12% AND >200ml increase in FEV1 after bronchodilator administration is considered significant reversibility.

Management Principles - Airway Allies

  • Goal: Relieve symptoms, prevent exacerbations, improve quality of life.
  • Asthma (GINA Guidelines):
    • Relief: As-needed low-dose ICS-Formoterol (preferred for ≥12 yrs) OR SABA.
    • Control: Stepwise approach. Key: Inhaled Corticosteroids (ICS). Add LABA, LAMA, LTRA, Biologics (Omalizumab, Mepolizumab) as needed.
    • Acute Attack: O2, SABA (nebulized), Systemic Steroids. Consider Ipratropium, MgSO4.
  • COPD (GOLD Guidelines):
    • Central: Smoking Cessation. Pulmonary Rehabilitation. Vaccinations (Influenza, Pneumococcal).
    • Pharmacotherapy:
      • Bronchodilators: LAMA (Tiotropium) and/or LABA (Salmeterol, Formoterol).
      • ICS: Add to LAMA/LABA if exacerbations (≥2 moderate/yr or ≥1 severe) OR blood eosinophils ≥300 cells/$\mu$L.
    • LTOT: $PaO_{2}$ ≤ 55 mmHg or $SaO_{2}$ ≤ 88%.
  • 📌 Inhaler Technique is CRUCIAL for all!

Types of inhalers and spacers

⭐ GINA 2023 recommends as-needed low-dose ICS-formoterol as the preferred reliever for adults and adolescents (≥12 years) with asthma across all severity steps.

High‑Yield Points - ⚡ Biggest Takeaways

  • Asthma: Reversible obstruction, eosinophilic inflammation, IgE often involved. COPD: Irreversible obstruction, neutrophilic inflammation, smoking is key cause.
  • Spirometry: FEV1/FVC < 0.7 for COPD diagnosis; reversibility points to asthma.
  • Treatment cornerstone: ICS for asthma; LABA/LAMA for COPD symptom management.
  • Exacerbations: Managed with SABAs, systemic steroids; antibiotics for infective COPD flares.
  • Smoking cessation is paramount in COPD. DLCO is typically ↓ in emphysema.

Practice Questions: Obstructive Airway Diseases (Asthma, COPD)

Test your understanding with these related questions

Which of the following medications should be avoided in a patient with asthma?

1 of 5

Flashcards: Obstructive Airway Diseases (Asthma, COPD)

1/10

Idiopathic pulmonary fibrosis presents clinically with progressive _____, cough, and digital clubbing

TAP TO REVEAL ANSWER

Idiopathic pulmonary fibrosis presents clinically with progressive _____, cough, and digital clubbing

dyspnea

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial